MedPAC Considering Two Options For Reinstating Medicare Least Costly Alternative Policy For Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Both proposals involve legislation that would authorize Medicare Part B to pay for drugs based on the price of the lowest-cost alternative.
You may also be interested in...
MedPAC Seeks Stakeholder Input On Medicare “Least Costly Alternative” Policy
Comments by members of the Medicare Payment Advisory Commission at a recent meeting suggest an opportunity for pharmaceutical industry stakeholders to help frame the discussion of Medicare value-based payment approaches for Part B drugs.
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.